Bristol-Myers Squibb (BMY - Get Report) and marketing partner Sanofi (SNY - Get Report) warned Friday that their earnings this year will take big hits from sales of a generic version of their Plavix blood-thinning drug.A federal judge Thursday ruled in the two companies' favor by ordering Apotex, the maker of generic Plavix, to halt sales. But the court didn't require Apotex to recall sales or shipments it has made since launching the generic on Aug. 8. Bristol-Myers and Sanofi said they¿re assuming plenty of damage has already been done.
Bristol-Myers, Sanofi Lower Guidance
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.